article thumbnail

Three trends in the antibody-drug conjugate (ADC) market 

Drug Discovery World

Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. A Nature publication confirmed that there are currently 12 FDA-approved ADCs on the market, and nine of these secured FDA approval in the past six years 2.

Marketing 245
article thumbnail

Sosei Heptares and Biohaven Enter Global Collaboration and License Agreement to Advance Novel Small-Molecule CGRP Antagonist Portfolio

The Pharma Data

Biohaven acquires exclusive global rights to a portfolio of novel, small-molecule CGRP antagonists. ” Shinichi Tamura , Chairman, President and CEO of Sosei Heptares, commented: “We are delighted to enter this collaboration and license agreement with Biohaven for our portfolio of novel CGRP receptor antagonists.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Key drug development trends and predictions for 2024

Drug Discovery World

This has been a real cause for concern for the industry, which is also facing growing competition in the investment market from big tech and AI. Financial landscape In 2023, life science companies experienced a significant decrease in funding, particularly seed funding for early-stage drug development.

article thumbnail

Immunotherapy for solid tumours progresses to human trials

Drug Discovery World

Research partners in the UK are progressing their orally available small molecule cancer immunotherapy drug into clinical development as a treatment for advanced solid tumours. HTL0039732 works by blocking signalling through a specific type of prostaglandin receptor, the prostaglandin E2 (PGE2)-type prostanoid receptor 4 (EP4).

Trials 130
article thumbnail

Taking a new approach to tackle neurodegenerative diseases

Drug Discovery World

Using its proprietary compound screening platform, Oligomerix discovers and develops differentiated, oral, small molecule inhibitors of tau self-association that are easy to administer and cost-effective. . Erhardt adds that despite the ever-increasing number of people with AD, there has been an erosion of market value (from $4.2

Disease 130
article thumbnail

UK’S MHRA GRANTS MARKETING AUTHORISATION FOR PFIZER’S CIBINQO® (ABROCITINIB) FOR.

The Pharma Data

This is the first marketing authorization globally for abrocitinib-. This is the first marketing authorization globally for abrocitinib-. Abrocitinib is licensed in Great Britain in recommended doses of 100mg and 200mg. This is the first marketing authorization worldwide for this treatment. “We

article thumbnail

U.S. FDA grants Priority Review for the Biologics License Application for Pfizer-BioNTech COVID-19 vaccine

The Pharma Data

Food and Drug Administration (FDA) granted Priority Review designation for the Biologics License Application (BLA) for their mRNA vaccine to prevent COVID-19 in individuals 16 years of age and older. The Pfizer-BioNTech COVID-19 vaccine has not been approved or licensed by the U.S. Pfizer Inc.